Radiation dosimetry and efficacy of an 89Zr/225Ac-labeled humanized anti-MUC5AC antibody-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Radiation dosimetry and efficacy of an 89Zr/225Ac-labeled humanized anti-MUC5AC antibody

Published:2022-05 Issue: Volume:108-109 Page:33-43
ISSN:0969-8051
Container-title:Nuclear Medicine and Biology
language:en
Short-container-title:Nuclear Medicine and Biology

Author:

Nakata Norihito,Kobashi Nobuya,Okumura Yuki,Sato Mikiko,Matono Mitsuhiro,Otsuki Kumiko,Tanaka Akihiro,Hayashi Akio

Funder

Office of Isotope R and D and Production

Japan Agency for Medical Research and Development

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Molecular Medicine

Reference27 articles.

1. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer;Kratochwil;J Nucl Med,2016

2. Preclinical evaluation of the acute radiotoxicity of the α-emitting molecular-targeted therapeutic agent 211At-MABG for the treatment of malignant pheochromocytoma in normal mice;Sudo;Transl Oncol,2019

3. Radioimmunotherapy of breast cancer metastases with α-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y;Song;Cancer Res,2009

4. Phase I trial of α-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia AML;Jurcic;J Clin Oncol,2015

5. 38;Tagawa;J Clin Oncol,2020

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-in-Human Total-Body PET/CT Imaging Using⁸⁹Zr-Labeled MUC5AC Antibody in a Patient with Pancreatic Adenocarcinoma;Journal of Nuclear Medicine;2024-09-05

2. Mucin Glycans: A Target for Cancer Therapy;Molecules;2023-10-11

3. Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future;Cancers;2023-10-03

4. Head‐to‐head comparison of three chelates reveals DOTAGA promising for ²²⁵Ac labeling of anti‐FZD10 antibody OTSA101;Cancer Science;2023-10-02

5. Development of Novel Trifunctional Chelating Agents That Enhance Tumor Retention of Radioimmunoconjugates;Journal of Medicinal Chemistry;2023-09-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3